↓ Skip to main content

Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic

Overview of attention for article published in Infectious Diseases and Therapy, June 2022

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter
16 X users

Readers on

mendeley
78 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic
Published in
Infectious Diseases and Therapy, June 2022
DOI 10.1007/s40121-022-00667-z
Pubmed ID
Authors

E. Ariza-Vioque, F. Ello, H. Andriamamonjisoa, V. Machault, J. González-Martín, M. C. Calvo-Cortés, S. Eholié, G. A. Tchabert, T. Ouassa, M. Raberahona, R. Rakotoarivelo, H. Razafindrakoto, L. Rahajamanana, R. J. Wilkinson, A. Davis, M. Maxebengula, F. Abrahams, C. Muzoora, N. Nakigozi, D. Nyehangane, D. Nanjebe, H. Mbega, R. Kaitano, M. Bonnet, P. Debeaudrap, J. M. Miró, X. Anglaret, N. Rakotosamimanana, A. Calmy, F. Bonnet, J. Ambrosioni

Abstract

Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified anti-tubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly in low- and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 78 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Master 7 9%
Student > Bachelor 6 8%
Lecturer 5 6%
Researcher 4 5%
Student > Postgraduate 3 4%
Other 6 8%
Unknown 47 60%
Readers by discipline
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Medicine and Dentistry 5 6%
Environmental Science 4 5%
Nursing and Health Professions 3 4%
Immunology and Microbiology 3 4%
Other 8 10%
Unknown 49 63%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2023.
All research outputs
#3,341,732
of 26,877,152 outputs
Outputs from Infectious Diseases and Therapy
#158
of 934 outputs
Outputs of similar age
#68,089
of 448,982 outputs
Outputs of similar age from Infectious Diseases and Therapy
#9
of 33 outputs
Altmetric has tracked 26,877,152 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 934 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,982 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.